呼吸道合胞病毒G蛋白的相关研究

呼吸道合胞病毒G蛋白介导病毒附着在宿主细胞表面,且具有亚型间抗原结构变异大的特点,其抗原变异推测是呼吸道合胞病毒逃避已存在免疫监视,引起反复感染的原因,了解G蛋白与免疫反应的关系对研制呼吸道合胞病毒亚单位疫苗,有效地防治该病毒感染具有重要意义。     

呼吸道合胞病毒在北京地区分离株G蛋白的基因分析

从经单克隆抗体证实为Ａ亚型的北京地区呼吸道合胞病毒（ＲＳＶ）分离株Ｂ７９中,用ＲＴ－ＰＣＲＴ扩增出编码Ｇ蛋白的基因片段,克隆至载体ｐＴＺ１８Ｒ中,经核苷酸序列测定证明,我国北京地区分离的Ａ亚型株Ｂ７９与ＲＳＶＡ亚型原型株（Ａ２株）Ｇ蛋白基因的核苷酸同源性为９３．８％,核苷酸的有义突变率为６５％,由核苷酸推导出氨基酸序列的同源性为８９．６％,氨基酸的变异主要集中在胞外区一个高度保守区的两端,而胞内区     

呼吸道合胞病毒G蛋白基因片段的克隆及高效表达

呼吸道合胞病毒(RSV)感染遍布全球,并可导致严重的疾病,但目前尚无成功的疫苗问世。为寻求可能用于RSV疫苗研制的重组蛋白抗原,我们在克隆RSV-A全长G蛋白基因的基础上,构建了多种共表达载体蛋白和G蛋白片段的表达载体,并从中筛选出能以可溶形式高效表达抗原蛋白的原核表达体系。通过亲和层析纯化了重组蛋白抗原DsbA-G101,将其免疫Balb／c小鼠后获得了相应的抗血清。经ELISA检测表明DsbA-G101具有良好的免疫原性。基于本研究所构建的系列表达载体,可以比较不同的G蛋白片段免疫原性的强弱及载体蛋白的优劣,从中发现最佳的RSV抗原蛋白。     

呼吸道合胞病毒疫苗研究进展

呼吸道合胞病毒(RSV)是引起严重下呼吸道感染的重要病原体,尽管经历了半个多世纪的努力,至今仍未有安全有效的RSV疫苗上市。近年来在RSV F蛋白结构生物学方面的研究进展为新一代RSV疫苗的开发提供了新方向,同时更多的采用不同技术、或针对不同人群的RSV侯选疫苗也在迅速发展,尤其是针对婴幼儿及老年人的RSV侯选苗已有60多种在研究中,大部分已处于临床前研究阶段,18种侯选苗已进入临床试验。我们简要介绍RSV疫苗的最新研究进展。     

呼吸道合胞病毒北京地区分离株G蛋白的基因分析

从经单克隆抗体证实为Ａ亚型的北京地区呼吸道合胞病毒（ＲＳＶ）分离株Ｂ７９中,用ＲＴ－ＰＣＲ扩增出编码Ｇ蛋白的基因片段,克隆至载体ｐＴＺ１８Ｒ中。经核苷酸序列测定证明,我国北京地区分离的Ａ亚型株Ｂ７９与ＲＳＶＡ亚型原型株（Ａ２株）Ｇ蛋白基因的核苷酸同源性为９３．８％,核苷酸的有义突变率达６５％。由核苷酸推导出氨基酸序列的同源性为８９．６％。氨基酸的变异主要集中在胞外区一个高度保守区的两端,而胞内区和跨膜区相对保守。本文探讨了我国北京地区ＲＳＶ分离株的Ｇ蛋白基因同原型株之间的变异,在疫苗研制中的意义。     

呼吸道合胞病毒B亚型分离株的G蛋白基因分析

对一株长春地区B亚型分离株(CC169)的G蛋白基因进行了 序列分析,结果表明：我国呼吸道合胞病毒(RSV)分离株CC169同RSV B亚型原型株CH18537的 核苷酸同源性为94%,核苷酸的有义突变率达65%。由核苷酸推导出氨基酸序列的同源性为894%,氨基酸的变异全部发生在胞外区,并主要集中在一个高度保守区的两端,胞内区和跨 膜区保守不变。氨基酸的变异导致了分离株既有糖基化位点的改变,又有蛋白长度的变异。 此外还初步探讨了我国RSV B 亚型分离株CC169的G蛋白基因同原型株之间的变异与疫苗研制 中的意义。     

呼吸道合胞病毒载体疫苗研究进展

人呼吸道合胞病毒(human respiratory syncytial virus, RSV)是引起婴幼儿下呼吸道感染的最重要的病毒病原,RSV载体疫苗可在人细胞内从头合成,形成的蛋白质构象与RSV自然感染后表达的完全相同,不会导致抗原表位的丧失或变化,形成的免疫力更利于抵抗随后的自然感染;经黏膜途径免疫不会产生疾病增强作用,且能突破母传抗体的干扰,因而受到广泛关注。对近年来RSV载体疫苗的研究进展进行了综述。     

基于融合蛋白的呼吸道合胞病毒疫苗的研究进展

呼吸道合胞病毒(respiratory syncytial virus,RSV)是一种引起严重下呼吸道感染的病原体,易感人群为婴幼儿、老年人及免疫功能低下者。目前尚无有效的抗病毒药物和预防疫苗。RSV融合蛋白(fusion protein,F蛋白)具有高度保守性,其诱导的抗体可同时抑制A型和B型两个亚型的RSV感染。因此,以F蛋白作为靶抗原的RSV亚单位疫苗、颗粒样疫苗和病毒载体疫苗是目前研究的主要策略。现就基于F蛋白的RSV疫苗研究进展作一综述。     

呼吸道合胞病毒F蛋白研究进展

人类呼吸道合胞病毒(RSV)融合蛋白(F蛋白)为病毒表面结构蛋白,可以刺激机体产生保护性抗体。因此对F蛋白的深入研究将有助于了解病毒感染的机理,从而为诊断试剂和亚单位疫苗的研制提供帮助。本文就F蛋白结构及结构与功能关系的研究进展进行简要综述。     

北京等四地区呼吸道合胞病毒分离株G蛋白基因的比较分析

为了解我国不同地区呼吸道合胞病毒（ＲＳＶ）感染特征是否与基因变异有关,对北京、广州、长春和河北四个地区不同流行特征中分离的ＲＳＶ毒株的Ｇ蛋白基因进行了序列分析。结果表明,该Ｇ蛋白基因同国外Ａ型亚原型株（Ａ２株）间存在显著差异,Ａ２株同分离株间的核苷酸同源性为９２．７－９３．６％,氨基酸同源性只有８８．３－８９．９％。分离株间的核苷酸同湃性为９６．０－９８．９％,氨基酸同源性９２．６－９７．７％。氨     

呼吸道合胞病毒G蛋白基因片段的克隆及高效表达

呼吸道合胞病毒(RSV)感染遍布全球,并可导致严重的疾病,但目前尚无成功的疫苗问世.为寻求可能用于RSV疫苗研制的重组蛋白抗原,我们在克隆RSV-A全长G蛋白基因的基础上,构建了多种共表达载体蛋白和G蛋白片段的表达载体,并从中筛选出能以可溶形式高效表达抗原蛋白的原核表达体系.通过亲和层析纯化了重组蛋白抗原DsbA-G101,将其免疫Balb/c小鼠后获得了相应的抗血清.经ELISA检测表明DsbA-G101具有良好的免疫原性.基于本研究所构建的系列表达载体,可以比较不同的G蛋白片段免疫原性的强弱及载体蛋白的优劣,从中发现最佳的RSV抗原蛋白.     

牛呼吸道合胞体病毒G蛋白的截短表达与鉴定

经生物学软件DNA Star分析,将牛呼吸道合胞体病毒G基因截短成2个片段G1和G2。然后用人工合成的牛呼吸道合胞体病毒G基因为模板,用PCR分别扩增G1和G2基因片段,其大小分别为570 bp和308 bp。将目的片段定向克隆到pET30a表达载体中,酶切及测序鉴定均正确后,转化BL21表达菌,经IPTG诱导后G1和G2基因片段都获得了表达,且都为可溶性表达。用Ni柱亲和层析法在非变性条件下纯化重组蛋白,经免疫印迹试验鉴定证明纯化的重组蛋白G1具有良好的抗原性和特异性,而重组蛋白G2无反应性。应用纯化的重组蛋白G1进行的间接ELISA与免疫印迹试验在国内牛血清中检测到了BRSV血清抗体。本研究所表达的重组蛋白G1为基于牛呼吸道合胞体病毒G蛋白的血清学诊断方法的建立与牛呼吸道合胞体病毒G蛋白生物学功能的研究奠定了基础。     

Systemic and mucosal immunity to respiratory syncytial virus induced by recombinant Streptococcus gordonii surface-displaying a domain of viral glycoprotein G

A conserved fragment comprising amino acid residues 130-230 of the G glycoprotein of human respiratory syncytial virus subtype A was expressed in the commensal bacterium Streptococcus gordonii. Recombinant streptococci displaying the G domain at the cell surface were used to immunize mice via both parenteral and mucosal routes. Subcutaneous immunization induced respiratory syncytial virus-specific serum immunoglobin G (IgG) capable of partially controlling virus replication in the lungs. Intranasal immunization with live bacteria stimulated the production of IgA against both the whole virus and the G domain in serum and bronchoalveolar fluid. Upon challenge, immunized animals had significantly lower virus titres in the lungs than the controls. Our results show for the first time that the G domain-expressing S. gordonii strain elicits both systemic and mucosal immunity that reduced respiratory syncytial virus replication in the lungs of mice.     

Biophysical characterization of G protein ectodomain of group B human respiratory syncytial virus from E. coli

Human respiratory syncytial virus (hRSV) is an important pathogen of acute respiratory tract infection. The G protein of hRSV is a transmembrane glycoprotein that is a neutralizing antigen and is thus a vaccine candidate. In this study, synthetic codon optimized ectodomain G protein [G(ΔTM)] of BA genotype of group B hRSV was cloned, expressed, and characterized using biophysical techniques. The molar absorption coefficient and mean residue ellipticity at 222 nm ([θ]222) of G (ΔTM) was found to be 7950 M^?1 cm^?1 and ?19701.7 deg cm² dmol^-1 respectively. It was concluded that G(ΔTM) mainly consist of α-helix (74.9%) with some amount of β-sheet (4%). The protein was stable up to 85°C without any transition curve. However, heat-induced denaturation of G(ΔTM) resulted in total loss of β-sheet whereas not much change was observed in the α-helix part of the secondary structure. It was concluded that G(ΔTM) is an α-helical protein and it is highly stable at high temperature, but could be easily denatured using high concentrations of GdmCl/urea or acidic condition. This is the first investigation of cloning, expression, and characterization of G(ΔTM) of BA viruses from India. Structural characterization of G protein will assist in drug designing and vaccine development for hRSV.     

Determination of the disulfide bond arrangement of human respiratory syncytial virus attachment (G) protein by matrix-assisted laser desorption/ionization time-of-flight mass spectrometry.

The attachment protein or G protein of the A2 strain of human respiratory syncytial virus (RSV) was digested with trypsin and the resultant peptides separated by reverse-phase high-performance liquid chromatography (HPLC). One tryptic peptide produced a mass by matrix-assisted laser desorption/ionization (MALDI) time-of-flight (TOF) mass spectrometry (MS) corresponding to residues 152-187 with the four Cys residues of the ectodomain (residues 173, 176, 182, and 186) in disulfide linkage and absence of glycosylation. Sub-digestion of this tryptic peptide with pepsin and thermolysin produced peptides consistent with disulfide bonds between Cys173 and Cys186 and between Cys176 and Cys182. Analysis of ions produced by post-source decay of a peptic peptide during MALDI-TOF-MS revealed fragmentation of peptide bonds with minimal fission of an inter-chain disulfide bond. Ions produced by this unprecedented MALDI-induced post-source fragmentation corroborated the existence of the disulfide arrangement deduced from mass analysis of proteolysis products. These findings indicate that the ectodomain of the G protein has a non-glycosylated subdomain containing a "cystine noose."     

The preventive effect of vaccine prophylaxis on severe respiratory syncytial virus infection:A meta-analysis

Respiratory syncytial virus(RSV) is the key underlying cause of acute lower respiratory tract infection in infants; however, no licensed vaccine against RSV infection is currently available. This study was undertaken to assess the preventive effect of vaccine on RSV infection. In this metaanalysis, 1,792 published randomized clinical trials of RSV vaccines from Jan 1973 to Sep 2015 were examined. Among thirteen studies that met the inclusion criteria, eleven studies estimated the impact of RSV vaccines and four studies estimated the effect of adjuvants. The odds ratios(ORs) were 0.31(95% CI, 0.15–0.67) and 0.62(95% CI, 0.29–1.34), respectively. We found that RSV subunit vaccines can significantly reduce the incidence of RSV infection and that whether vaccination with adjuvant therapy was an effective strategy still remained to be studied. This analysis of the preventive effect of vaccines on RSV infection has direct applications for the prevention of RSV infections.     

Oral immunization of mice with transgenic tomato fruit expressing respiratory syncytial virus-F protein induces a systemic immune response

Respiratory syncytial virus (RSV) is one of the most important pathogens of infancy and early childhood. Here a fruit-based edible subunit vaccine against RSV was developed by expressing the RSV fusion (F) protein gene in transgenic tomato plants. The F-gene was expressed in ripening tomato fruit under the control of the fruit-specific E8 promoter. Oral immunization of mice with ripe transgenic tomato fruits led to the induction of both serum and mucosal RSV-F specific antibodies. The ratio of immunoglobulin subclasses produced in response to immunization suggested that a type 1 T-helper cell immune response was preferentially induced. Serum antibodies showed an increased titer when the immunized mice were exposed to inactivated RSV antigen.